{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:47:42Z","timestamp":1782755262907,"version":"3.54.5"},"reference-count":14,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis and psoriatic arthritis are chronic immune-mediated diseases with both physical and psychological consequences. Depression is a common comorbidity associated with impaired quality of life and lower treatment adherence. Biologics, monoclonal antibodies targeting key cytokines, may favorably influence depressive symptoms by reducing systemic inflammation and improving disease activity. However, current evidence is heterogeneous and has not been comprehensively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis will evaluate whether biologic therapy reduces the risk of depression among adults with psoriasis or psoriatic arthritis compared with non-biologic treatment or no therapy. Electronic searches will include MEDLINE, Embase, Cochrane Library, PsycINFO, and ClinicalTrials.gov. Eligible designs are randomized controlled trials (RCTs), cohort, and case\u2013control studies reporting depression incidence or prevalence. Depression may be ascertained through clinical diagnosis or validated instruments. Study selection, data extraction, and risk-of-bias assessment will be performed independently by two reviewers. Using the Cochrane Risk of Bias 2.0 tool and the Newcastle\u2013Ottawa Scale, we will assess quality of each study. Data permitting, random-effects meta-analysis will estimate pooled risk ratios (RRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Certainty of evidence will be rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This review will synthesize the impact of biologic therapy on incident depression in psoriasis and psoriatic arthritis, informing integrated care for patients with psoriatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO (submitted; registration number to be confirmed prior to data extraction).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351646","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:26:55Z","timestamp":1782754015000},"page":"e0351646","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of depression in patients with psoriasis and psoriatic arthritis treated with biologic therapy: Protocol for a systematic review and meta-analysis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-8543","authenticated-orcid":true,"given":"Emily","family":"Sirotich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2935-4900","authenticated-orcid":true,"given":"Weston","family":"Lowry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5784","authenticated-orcid":true,"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2979-7280","authenticated-orcid":true,"given":"Madison","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"12","key":"pone.0351646.ref001","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1007\/s13555-023-01060-5","article-title":"Psychosocial burden of psoriasis: A systematic literature review of depression among patients with psoriasis","volume":"13","author":"PC Luna","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"pone.0351646.ref002","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40257-024-00877-w","article-title":"Association between biologic exposure and the risk of depression in patients with psoriasis: A retrospective analysis of large US administrative claims data","volume":"25","author":"B Strober","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"pone.0351646.ref003","first-page":"1096","article-title":"Interleukin-17 and -23 inhibitors associated with direct effects on depressive symptoms in psoriasis: Results from a register study","volume":"33","author":"A Egeberg","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"pone.0351646.ref004","first-page":"1271","article-title":"Association between secukinumab exposure and risk of depression in patients with psoriasis","volume":"179","author":"Y Seko","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"pone.0351646.ref005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2017.08.051","article-title":"Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"78","author":"B Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0351646.ref006","article-title":"Association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs","volume":"5","author":"F Behrens","year":"2019","journal-title":"RMD Open"},{"key":"pone.0351646.ref007","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation","volume":"349","author":"L Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"pone.0351646.ref008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Statement","volume":"4","author":"D Moher","year":"2015","journal-title":"Syst Rev"},{"key":"pone.0351646.ref009","author":"HK Grossetta Nardini","year":"2021"},{"key":"pone.0351646.ref010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 guideline statement","volume":"75","author":"J McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"pone.0351646.ref011","year":"2023"},{"key":"pone.0351646.ref012","year":"2021"},{"key":"pone.0351646.ref013","year":"2023"},{"key":"pone.0351646.ref014","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jclinepi.2020.09.018","article-title":"GRADE Guidelines 30: The GRADE approach to assessing the certainty of modeled evidence\u2014an overview in the context of health decision-making","volume":"129","author":"JL Brozek","year":"2021","journal-title":"J Clin Epidemiol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:26:58Z","timestamp":1782754018000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351646"}},"subtitle":[],"editor":[{"given":"Pavel V.","family":"Chernyshov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351646","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}